The salient findings of the present study are as follows: (1) overexpression of the ADMA degrading enzyme, DDAH1, does not reduce plaque formation in SNX treated ApoE-deficient mice; and (2) CKD in mice induced by SNX does not affect plasma levels of ADMA. This evidence concerns the gene DDAH1 and chronic kidney disease.